NCT04609488

Surfactant Levels in the Lungs of COVID-19 Patients

An Exploratory Study to Assess Surfactant Levels in COVID-19 Patients Who Will be on Ventilatory Support Due to Severe Respiratory Failure

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Zealand University Hospital · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

NAME of STUDY: Surfactant levels in the lungs of COVID-19 patients BACKGROUND * Infection with SARS-CoV-2 may induce respiratory failure. * COVID-19 associated respiratory failure may require ventilatory support. * SARS-CoV-2 uses alveolar type II cells for virus replication. * Alveolar type II cells are responsible for surfactant production and lack of surfactant causes respiratory failure in preterm neonates. * Lack of surfactant may play role for respiratory failure in COVID-19 patients DESIGN Exploratory prospective study design without therapeutic intervention of any kind. Lung fluid will be donated as part of standard care procedures. HYPOTHESIS Surfactant is measurable in tracheal secretions by mid-infrared FTIR spectroscopy determined surfactant spectra. Surfactant is reduced in COVID-19 patients requiring ventilator support as compared to non- COVID-19 patients. Dysfunctional surfactant in COVID-19 patients regain its function when respiratory function improves. POPULATION Main population is patients with COVID-19 pneumonia that requires ventilatory support. OUTCOME MEASURES Primary outcome is the level of surfactant in lung fluid as obtained by tracheal suction. SAMPLE SIZE In total 30 patients will be included: twenty COVID-19 patients and 10 non-COVID-19 patients.

Conditions

• To Assess Surfactant Levels in Lung Fluid

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Surfactant assessment	To determine surfactant levels in lung fluid

Timeline

• Start date: 2020-11-01
• Primary completion: 2022-09-30
• Completion: 2022-10-01
• First posted: 2020-10-30
• Last updated: 2020-10-30